Our Research Posters on Drug Development | Gain Therapeutics
Neuroscience 2025
GT-02287, a Small Molecule Allosteric Modulator of the Lysosomal Enzyme Glucocerebrosidase (GCase), Also Affects GCase at the Level of the Mitochondria
GT-02287, A Clinical-stage Allosteric GCase Modulator For The Treatment Of Parkinson’s Disease, Protects Dopaminergic Neurons Against Mitochondrial Toxin MPP+
2024 International Congress of Parkinson’s Disease and Movement Disorders
The novel glucocerebrosidase chaperone GT-02287 in development for GBA-PD is safe and well tolerated in healthy volunteers at oral doses that produce plasma exposures in the projected therapeutic range
GT-02287, a Clinical-Stage GCase Enhancer, Improves Activities of Daily Living and Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
GT-02287, a clinical stage GCase enhancer, displays neuroprotection and restores motor function in preclinical models of Parkinson’s disease following delayed administration
2023 International Congress of Parkinson's Disease and Movement Disorders®
GT-02287, a clinical stage GCase enhancer, displays neuroprotection and restores motor function in preclinical models of Parkinson’s disease following delayed administration
2023 International Congress of Parkinson's Disease and Movement Disorders®
GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase shows evidence of pharmacological efficacy in an animal model of Parkinson’s disease
Small-Molecule Structurally Targeted Allosteric Regulators Of Glucocerebrosidase Show Neuroprotective Properties In Cell-Based Models Of Alzheimer’s Disease
GT-02329, a structurally targeted allosteric regulator of GCase, restores GCase activity, reduces microgliosis and improves fine locomotor skills in the CBE model of neuronopathic Gaucher’s disease
XXVII World Congress on Parkinson’s Disease and Related Disorders
GT-02287, a Brain-Penetrant Structurally Targeted Allosteric Regulator for Glucocerebrosidase Shows Evidence of Pharmacological Efficacy in Models of Parkinson’s Disease
International Congress of Parkinson’s Disease and Movement Disorders 2022 Annual Meeting
GT-02287, A Brain-penetrant Structurally Targeted Allosteric Regulator of Glucocerebrosidase Shows Evidence of Pharmacological Efficacy in Conduritol β-epoxide (CBE) Models of Parkinson’s Disease
AD/PD™ 2022 International Conference on Alzheimer's and Parkinson's Diseases
Brain-penetrant structurally targeted allosteric regulators for glucocerebrosidase (GCase) show promising pharmacological activity in models of neurodegenerative diseases
World Congress on Parkinson’s Disease and Related Disorders 2021
Preclinical development of brain-penetrant structurally targeted allosteric regulators for the treatment of GBA1 Parkinson’s disease and related alpha-synucleopathies
